id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-256565-59bnifxm	Lebwohl, Mark	Reply to: “COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution”	2020-04-10		.txt	text/plain	502	37	49	title: Reply to: "COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution" Reply to: ''COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution'' To the Editor: We thank Dr Kansal 1 from the All India Institute of Medical Sciences for her pertinent comments in response to our publication on the use of biologic agents for psoriasis patients in the current COVID-19 pandemic. To be clear, we cannot know the long-term impact of biologic agents on patients with suspected or confirmed COVID-19 until more time passes and we have more data. For now, the most medical organizations, including the American Academy of Dermatology, the National Psoriasis Foundation, and the International Eczema Council, among others, have advocated not discontinuing biologics in patients who are not infected. Of course, these agents should be discontinued in patients with active infection. COVID-19, syphilis and biologic therapies for psoriasis andpsoriatic arthritis: a word of caution	./cache/cord-256565-59bnifxm.txt	./txt/cord-256565-59bnifxm.txt